Cargando…
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
BACKGROUND: Focal adhesion kinase (FAK) inhibitors have demonstrated anti-tumor activity preclinically and are currently being evaluated in humans. A first-in-human study evaluating the novel FAK inhibitor BI 853520 in a predominantly Caucasian population with advanced or metastatic non-hematologic...
Autores principales: | Doi, Toshihiko, Yang, James Chih-Hsin, Shitara, Kohei, Naito, Yoichi, Cheng, Ann-Lii, Sarashina, Akiko, Pronk, Linda C., Takeuchi, Yoshito, Lin, Chia-Chi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407737/ https://www.ncbi.nlm.nih.gov/pubmed/30725402 http://dx.doi.org/10.1007/s11523-019-00620-0 |
Ejemplares similares
-
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
por: de Jonge, Maja J. A., et al.
Publicado: (2019) -
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520
por: Verheijen, Remy B., et al.
Publicado: (2019) -
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype
por: Hirt, Ulrich A., et al.
Publicado: (2018) -
The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
por: Tiede, Stefanie, et al.
Publicado: (2018) -
Focal adhesion kinase inhibitor BI 853520 inhibits cell proliferation, migration and EMT process through PI3K/AKT/mTOR signaling pathway in ovarian cancer
por: Li, Hong, et al.
Publicado: (2021)